Forward Pharma A/S Stock Forecast, Price & News

Wall Street analysts have given Forward Pharma A/S a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Forward Pharma A/S wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Forward Pharma A/S saw a decrease in short interest during the month of August. As of August 31st, there was short interest totaling 22,700 shares, a decrease of 27.2% from the August 15th total of 31,200 shares. Based on an average trading volume of 408,900 shares, the days-to-cover ratio is presently 0.1 days. Approximately 0.3% of the company's shares are sold short.
View Forward Pharma A/S's Short Interest.

Forward Pharma A/S (NASDAQ:FWP) released its quarterly earnings data on Thursday, September, 1st. The biotechnology company reported ($0.32) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.26) by $0.06.
View Forward Pharma A/S's earnings history.

Forward Pharma A/S's stock was trading at $5.55 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, FWP shares have increased by 17.3% and is now trading at $6.51.
View which stocks have been most impacted by COVID-19.

Some companies that are related to Forward Pharma A/S include Actinium Pharmaceuticals (ATNM), Sol-Gel Technologies (SLGL), Mereo BioPharma Group (MREO), Enlivex Therapeutics (ENLV), Entasis Therapeutics (ETTX), Tyme Technologies (TYME), Hookipa Pharma (HOOK), Aquestive Therapeutics (AQST), Sio Gene Therapies (SIOX), Calithera Biosciences (CALA), Milestone Pharmaceuticals (MIST), Synlogic (SYBX), SELLAS Life Sciences Group (SLS), Anebulo Pharmaceuticals (ANEB) and Aptinyx (APTX).
View all of FWP's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Forward Pharma A/S investors own include Gilead Sciences (GILD), SCYNEXIS (SCYX), AbbVie (ABBV), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Celldex Therapeutics (CLDX), Catalyst Pharmaceuticals (CPRX), Micron Technology (MU), Nabriva Therapeutics (NBRV) and Onconova Therapeutics (ONTX).

Forward Pharma A/S trades on the NASDAQ under the ticker symbol "FWP."

Forward Pharma A/S's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BVF Inc. IL (7.67%), Morgan Stanley (2.64%) and Morgan Stanley (2.64%).

FWP stock was sold by a variety of institutional investors in the last quarter, including BVF Inc. IL.

FWP stock was acquired by a variety of institutional investors in the last quarter, including Morgan Stanley, and Morgan Stanley.

Shares of FWP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of FWP stock can currently be purchased for approximately $6.51.

Forward Pharma A/S has a market capitalization of $44.87 million.

Forward Pharma A/S employs 4 workers across the globe.

The official website for Forward Pharma A/S is www.forward-pharma.com.

Forward Pharma A/S is headquartered at OSTERGADE 24A 1, COPENHAGEN G7, 1100.

Forward Pharma A/S's mailing address is OSTERGADE 24A 1, COPENHAGEN G7, 1100. The biotechnology company can be reached via phone at (453) 344-4242 or via email at [email protected].